0001217234-26-000059
SEC filingCareDx第三季度营收1.39亿美元同比增39%，检测服务与NavDx并表驱动，全年指引上调。
| 指标 | 本期 | 去年同期 | 同比 |
|---|---|---|---|
| Revenue | $139 million | $100 million | 39% |
| Gross Margin (GAAP) | 71% | 69% | — |
| Gross Margin (Non-GAAP) | 74% | 71% | — |
| Operating Income (GAAP) | $8.112 million | $(0.246) million | — |
| Net Income (GAAP) | $19.292 million | $1.675 million | — |
| Net Income (Non-GAAP) | $38.368 million | $14.896 million | — |
| Diluted EPS (GAAP) | $0.35 | $0.03 | — |
| Diluted EPS (Non-GAAP) | $0.70 | $0.28 | — |
| Adjusted EBITDA | $30.496 million | $15.299 million | — |
| Adjusted EBITDA Margin | 22% | 15% | — |
| Testing Services Revenue | $119.191 million | $72.168 million | 65% |
| Patient and Digital Solutions Revenue | $20.171 million | $15.409 million | 31% |
| 期间 | 指标 | 指引 | 口径 |
|---|---|---|---|
| FY2026 | Revenue | $520 million to $530 million | N/A |
| FY2026 | Adjusted EBITDA | $90 million to $100 million | Non-GAAP |
第三季度营收$139 million、同比增长39%，主要由Testing Services（$119 million，+65%）和Patient and Digital Solutions（$20 million，+31%）拉动；Testing Services含NavDx并表带来的$12 million Specialty Oncology收入，以及$15 million前期确认收入（去年同期$6 million），剔除前期收入后Testing Services增速约58%。Lab Products已于2026年6月30日剥离，故本期不含其收入，同比口径需注意。
利润率方面，GAAP毛利率71%（去年同期69%），Non-GAAP毛利率74%（去年同期71%）；GAAP净利润$19 million、净利率约14%，其中含$8.6 million所得税收益，Non-GAAP净利润$38 million。Adjusted EBITDA $30 million、利润率约22%，公司归因于收入增长、毛利提升与费用纪律。经营现金流$13 million、自由现金流$11 million，明显低于去年同期的$37 million和$36 million。管理层将全年营收指引由$490–500 million上调至$520–530 million，Adjusted EBITDA指引由$66–78 million上调至$90–100 million；7月1日完成Naveris收购（现金对价$160 million加最高$100 million或有对价），期末现金及等价物$250.480 million。